Compare Levi Strauss & Co. (LEVI) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Levi Strauss & Co. vs Sanofi SA — how do they compare? Levi Strauss & Co. trades at $18.69 (market cap $7.31B), while Sanofi SA trades at $40.13 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 13× Levi Strauss & Co.'s market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Levi Strauss & Co. for 70 Days and Sanofi SA for 94 Days on average.
| LEVI | SNY | |
|---|---|---|
Market Cap | $7.31B | $95.18B |
Volume | 13,683,095 | 2,995,646 |
Sector | Consumer Cyclical | Health |
52-Week High | $25.53 | $52.34 |
52-Week Low | $17.92 | $39.51 |
Typical Hold Time | 70 Days | 94 Days |
Enterprise Value | $8.86B | $114.48B |
Dividend Yield | 3.36% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Levi Strauss (LEVI) trades at $18.71, down 4.13% today, with a bearish technical outlook despite strong fundamentals. The company has beaten earnings estimates for four consecutive quarters, maintains a healthy gross margin of 62.81%, and shows improving cash flow trends. Analyst consensus remains strongly bullish with a $29.00 price target, representing 55% upside potential from current levels.
The stock presents a compelling value opportunity with a P/E of 12.5x and strong brand momentum, though technical weakness and recent cybersecurity incidents pose near-term risks. Wall Street's overwhelming buy rating (79%) suggests confidence in Levi's direct-to-consumer strategy and international expansion driving future growth.
SNY trades at $40.17, down slightly by 0.07%. The technical outlook is bearish, with price near key support at $40. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling growth potential beyond its blockbuster drug Dupixent.
The stock presents a mixed outlook. Positive factors include consistent earnings beats, a high gross margin of 72.77%, and strategic partnerships. However, a bearish technical signal, a projected net income decline to $4.0B in 2026, and a high proportion of analyst hold ratings (51.86%) suggest caution. Key risks involve execution of new drug pipelines and future patent expirations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
